Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-05-01T07:22:14.360Z Has data issue: false hasContentIssue false

19 - Psychopharmacology in intellectual disabilities

from Part III - Treatment and therapeutic interventions

Published online by Cambridge University Press:  15 December 2009

Bryan King
Affiliation:
Professor and Vice Chair of Psychiatry and Behavioural Sciences, University of Washington
Nick Bouras
Affiliation:
King's College London
Geraldine Holt
Affiliation:
King's College London
Get access

Summary

Introduction

Little controversy surrounds the notion that persons with intellectual disabilities (ID) may engage in disruptive and challenging behaviours. One of the common referral queries to clinicians of people with ID – ‘Is this a mental illness or just a problem behaviour?’ – tends to stir up more discussion. At one extreme, attempts to understand maladaptive behaviours are merely descriptive and simply default to the ID itself. For example, aggression or self-injurious behaviour is said to be a product of the individual's cognitive disability and does not warrant a ‘diagnosis’. At the same time, the degree to which an individual is held accountable for his behaviour is also placed into consideration, as is the appropriateness of pharmacotherapy, depending on the answer to the referral question.

At the other extreme, an attempt is made to identify a syndrome or disorder within which the behaviour in question can be understood — to cast the behaviour at issue as the manifestation of a physiological abnormality. For example, the self-injurious or aggressive behaviour may be viewed as a symptom of a mood disorder (see also Chapter 4 by Hemmings). Such attempts clearly carry therapeutic implications, and can be traced back to the origins of the psychiatry of ID.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Advokat, C. D., Mayville, E. A. & Matson, J. L.Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Research in Developmental Disabilities. 21(1):75–84, 2000.
Agarwal, V., Sitholey, P., Kumar, S. & Prasad, M., Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation. Mental Retardation. 39(4):259–67, 2001.
Ahmed, Z., Fraser, W., Kerr, M. P.et al. Reducing antipsychotic medication in people with a learning disability. British Journal of Psychiatry. 176:42–6, 2000.
Aman, M. G.Efficacy of psychotropic drugs for reducing self-injurious behavior in the developmental disabilities. Annals of Clinical Psychiatry. 5:171–188, 1993.
Aman, M. G., Smedt, G., Derivan, A., Lyons, B.F & Findling, R. L.Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. American Journal of Psychiatry. 159(8):1337–46, 2002.Google Scholar
Aman, M. G., Kern, R. A., McGhee, D. E. & Arnold, L. E.Fenfluramine and methylphenidate in children with mental retardation and ADHD: clinical and side effects. Journal of the American Academy of Child & Adolescent Psychiatry. 32(4):851–9, 1993.Google Scholar
Aman, M. G., Marks, R. E., Turbott, S. H., Wilsher, C. P. & Merry, S. N.Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. Journal of the American Academy of Child & Adolescent Psychiatry. 30(2):246–56, 1991.Google Scholar
,Anonymous. Expert Consensus Guideline Series: Treatment of psychiatric and behavioral problems in mental retardation. American Journal of Mental Retardation. 105(3):159–226, 2000.Google Scholar
Barron, J. & Sandman, C. A.Paradoxical excitement to sedative-hypnotics in mentally retarded clients. American Journal of Mental Deficiency. 90(2):124–9, 1985.Google Scholar
Baumeister, A. A., Sevin, J. A. & King, B. H. Neuroleptics. In Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook, ed. Reiss, S. & Aman, M., Columbus, OH: Ohio State University Nisonger Center, pp. 133–50, 1998.
Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J. & Zimmerman, A. W.Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Autism & Developmental Disorders. 31(2):175–81, 2001.Google Scholar
Beran, R. G. & Gibson, R. J.Aggressive behavior in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia. 39(3):280–2, 1998.Google Scholar
Bodfish, J. W., Newell, K. M., Sprague, R. L., Harper, V. N. & Lewis, M. H.Dyskinetic movement disorder among adults with mental retardation: phenomenology and co-occurrence with stereotypy. American Journal of Mental Retardation, 101:118–29, 1996.Google Scholar
Bucknill, J. C. & Tuke, D. H. (1858). A manual of psychological medicine: containing the history, nosology, description, statistics, diagnosis, pathology, and treatment of insanity, with an appendix of cases. Philadelphia, PA: Blanchard and Lea, 1858.
Buitelaar, J. K., Gaag, R. J., Cohen-Kettenis, P. & Melman, C. T.A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry. 62(4):239–48, 2001.Google Scholar
Clark, R. D., Canive, J. M., Calais, L. A., Qualls, C. R. & Tuason, V. B.Divalproex in post-traumatic stress disorder: an open-label clinical trial. Journal of Traumatic Stress. 12(2):395–401, 1999.Google Scholar
Cohen, S., Glazewski, R., Khan, S. & Khan, A.Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. Journal of Clinical Psychiatry. 62(2):114–16, 2001.Google Scholar
Coppola, G., Iervolino, G., Mastrosimone, M., Torre, G., Ruiu, F. & Pascotto, A.Melatonin in wake–sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain & Development. 26(6):373–6, 2004.Google Scholar
Crawford, P., Brown, S. & Kerr, M.Parke Davis Clinical Trials Group. A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. Seizure. 10(2):107–15, 2001.Google Scholar
Davanzo, P. A. & King, B. H.Open trial of lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation. Journal of Child and Adolescent Psychopharmacology. 6:273–9, 1996.Google Scholar
Devinsky, O.Cognitive and behavioral effects of antiepileptic drugs. Epilepsia. 36 (Suppl. 2):S46–65, 1995.Google Scholar
Diamond, A.Evidence for the importance of dopamine for prefrontal cortex functions early in life. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. 351:1483–93, 1996.Google Scholar
Dykens, E. & Shah, B.Psychiatric disorders in Prader–Willi syndrome: epidemiology and management. CNS Drugs. 17(3):167–78, 2003.Google Scholar
Friedlander, R., Lazar, S. & Klancnik, J.Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Canadian Journal of Psychiatry. 46(8):741–5, 2001.Google Scholar
Gail Williams, P., Sears, L. L. & Allard, A.Sleep problems in children with autism. Journal of Sleep Research. 13(3):265–8, 2004.Google Scholar
Gedye, A.Dietary increase in serotonin reduces self-injurious behaviour in a Down syndrome adult. Journal of Mental Deficiency Research. 34:195–203, 1990.Google Scholar
Hammock, R., Levine, W. R. & Schroeder, S.Brief report: effects of clozapine on self-injurious behaviour of two risperidone nonresponders with mental retardation. Journal of Autism & Developmental Disorders. 31(1):109–13, 2001.Google Scholar
Handen, B. J., Breaux, A. M., Janosky, J.et al. Effects and noneffects of methylphenidate in children with mental retardation and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry. 31:455–61, 1992.Google Scholar
Handen, B. L., Feldman, A., Goslingi, A. M. & McAuliffe, S. Adverse side effects of methyl-phenidate among mentally retarded children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry. 30:241–5, 1991.
Handen, B. L., Janosky, J., McAuliffe, S., Breaux, A. M. & Feldman, H.Prediction of response to methylphenidate among children with ADHD and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 33:1185–93, 1994.Google Scholar
Hellings, J. A. & Warnock, J. K.Self-injurious behaviour and serotonin in Prader–Willi syndrome. Psychopharmacology Bulletin. 30:245–50, 1994.Google Scholar
Hellings, J. A., Zarcone, J. R., Crandall, K., Wallace, D. & Schroeder, S. R.Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of Child & Adolescent Psychopharmacology. 11(3):229–38, 2001.Google Scholar
Hirayama, T., Kobayashi, T., Fujita, T. & Fujino, O.Two cases of adult Down syndrome treated with selective serotonin re-uptake inhibitor for behaviour disorders. No to Hattatsu [Brain & Development]. 36(5):391–4, 2004.Google Scholar
Ireland, W. W.Mental Affections of Children, Idiocy, Imbecility and Insanity. Oxford: Churchill, 1898.
Jambaque, I., Chiron, C., Dumas, C., Mumford, J. & Dulac, O.Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Research. 38(2–3):151–60, 2000.Google Scholar
Jan, M. M.Melatonin for the treatment of handicapped children with severe sleep disorders. Pediatric Neurology. 23(3):229–32, 2000.Google Scholar
Johnson, C. R., Handen, B. L.Lubetsky, M. J. & Sacco, K. A.Efficacy of methylphenidate and behavioral intervention on classroom behavior in children with ADHD and mental retardation. Behavior Modification. 18(4):470–87, 1994.Google Scholar
Kalachnik, J. E., Hanzel, T. E., Sevenich, R. & Harder, S. R.Benzodiazepine behavioural side effects: review and implications for individuals with mental retardation. American Journal of Mental Retardation. 107(5):376–410, 2002.Google Scholar
Kalachnik, J. E., Leventhal, B. L., James, D. H. et al. Guidelines for the use of psychotropic medication. In Reiss, S. & Aman, M. G. (eds.), Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, OH: Ohio State University, pp. 45–72, 1998.
King, B. H. Pemoline and other dopaminergic models of self-biting behavior. In Schroeder, S. R. & Oster-Granite, M. L. (eds.), Self-injurious Behavior: Gene-Brain-Behavior Relationships. Washington, DC: American Psychological Association, pp. 181–89, 2002.
King, B. H.Self-injury by people with mental retardation: a compulsive behavior hypothesis. American Journal of Mental Retardation. 98(1):93–112, 1993.Google Scholar
King, B. H., DeAntonio, C., McCracken, J. T., Forness, S. R. & Ackerland, V.Psychiatric consultation in severe and profound mental retardation. American Journal of Psychiatry, 151:1802–8, 1994.Google Scholar
King, B. H. & Davanzo, P. A.Buspirone treatment of aggression and self-injury in autistic and non autistic persons with severe mental retardation. Developmental Brain Dysfunction. 9:22–31, 1996.Google Scholar
King, B. H. & Wright, D. M., Snape, M. & Dourish, C. T.Case series: amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. Journal of the American Academy of Child & Adolescent Psychiatry. 40(6):654–7, 2001.Google Scholar
Kockelmann, E., Elger, C. E. & Helmstaedter, C.Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and co-medication. Epilepsy & Behaviour. 5(5):716–21, 2004.Google Scholar
LeVann, L. J.Thioridazine (Mellaril): A psycho-sedative virtually free of side-effects. Alberta Medical Bulletin, 26:144–7, 1961.Google Scholar
Lewis, M. H., Bodfish, J. W., Powell, S. B., Parker, D. E. & Golden, R. N.Clomipramine treatment for self-injurious behaviour of individuals with mental retardation: a double-blind comparison with placebo. American Journal of Mental Retardation. 100:654–65, 1996.Google Scholar
Lewis, M. A., Lewis, C. E.Leake, B., King, B. H. & Lindemann, R.The quality of health care for adults with developmental disabilities. Public Health Reports. 117(2):174–84, 2002.Google Scholar
Masi, G., Marcheschi, M. & Pfanner, P.Paroxetine in depressed adolescents with intellectual disability: an open label study. Journal of Intellectual Disability Research. 41(Pt 3):268–72, 1997.Google Scholar
McDonough, M., Hillery, J. & Kennedy, N.Olanzapine for chronic, stereotypic self-injurious behaviour: a pilot study in seven adults with intellectual disability. Journal of Intellectual Disability Research. 44(Pt 6):677–84, 2000.Google Scholar
Pearson, D. A., Santos, C. W., Casat, C. D.et al. Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD. Journal of the American Academy of Child & Adolescent Psychiatry. 43(6):677–85, 2004.Google Scholar
Pillar, G., Shahar, E., Peled, N., Ravid, S., Lavie, P. & Etzioni, A.Melatonin improves sleep-wake patterns in psychomotor retarded children. Pediatric Neurology. 23(3):225–8, 2000.Google Scholar
Racusin, R., Kovner-Kline, K. & King, B. H.Selective serotonin reuptake inhibitors in intellectual disability. Mental Retardation & Developmental Disabilities Research Reviews. 5(4): 264–9, 1999.Google Scholar
Ratey, J. J. & Gordon, A.The psychopharmacology of aggression: toward a new day. Psychopharmacology Bulletin, 29:65–73, 1993.Google Scholar
Ratey, J. J., Sovner, R., Mikkelsen, E. & Chmielinski, H. E. Buspirone therapy for maladaptive behaviour and anxiety in developmentally disabled persons. Journal of Clinical Psychiatry. 50:382–4, 1989.Google Scholar
Robertson, J., Emerson, E.Gregory, N.et al. A. Receipt of psychotropic medication by people with intellectual disability in residential settings. Journal of Intellectual Disability Research. 44 (Pt 6):666–76, 2000.Google Scholar
Sachdev, P.Drug-induced movement disorders in institutionalised adults with mental retardation: clinical characteristics and risk factors. Australian and New Zealand Journal of Psychiatry. 26:242–8, 1992.Google Scholar
Santosh, P. J. & Baird, G.Psychopharmacotherapy in children and adults with intellectual disability. Lancet. 354(9174):233–42, 1999.Google Scholar
Schroeder, S. R., Oster-Granite, M. L., Berkson, G.et al. Self-injurious behavior: gene–brain–behavior relationships. Mental Retardation & Developmental Disabilities Research Reviews. 7(1):3–12, 2001.Google Scholar
Schweitzer, I.Does risperidone have a place in the treatment of nonschizophrenic patients?International Clinical Psychopharmacology. 16(1):1–19, 2001.Google Scholar
Sutherland, S. M. & Davidson, J. R.Pharmacotherapy for post-traumatic stress disorder. Psychiatric Clinics of North America. 17:409–23, 1994.Google Scholar
Szymanski, L. & King, B. H.Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. Journal of the American Academy of Child & Adolescent Psychiatry. 38 (Suppl. 12):5–31, 1999.Google Scholar
Trimble, M. R.Epilepsy, antidepressants, and the role of nomifensine. Journal of Clinical Psychiatry. 45(4 Pt 2):39–42, 1984.Google Scholar
Tsiouris, J. A., Cohen, I. L., Patti, P. J. & Korosh, W. M. Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behaviour. Journal of Clinical Psychiatry. 64(9):1081–90, 2003.Google Scholar
Tu, J. B. & Zellweger, H.Blood-serotonin deficiency in Down syndrome. Lancet. 2(7415):715–16, 1965.Google Scholar
Tuke, D. H.The Insane in the United States and Canada. London: H. K. Lewis. (1885).
Turgay, A., Binder, C., Snyder, R. & Fisman, S.Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics. 110(3):e34, 2002.Google Scholar
Turner, C. A. & Lewis, M. H. Dopaminergic mechanisms in self-injurious behavior and related disorders. In: Schroeder, S. R. & Oster-Granite, M. L. (eds.), Self-injurious Behavior: Gene–Brain–Behavior Relationships. Washington, DC: American Psychological Association. pp. 165–179, 2002.
Bellinghen, M. & Troch, C.Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. Journal of Child & Adolescent Psychopharmacology. 11(1):5–13, 2001.Google Scholar
Verhoeven, W. M., Moog, U., Wagemans, A. M., Tuinier, S. & Wolf-Hirschhorn, (4p-) syndrome in a near adult with major depression; successful treatment with citalopram. Genetic Counseling. 13(3):297–301, 2002.Google Scholar
Verhoeven, W. M. & Tuinier, S.The effect of buspirone on challenging behaviour in mentally retarded patients: an open prospective multiple-case study. Journal of Intellectual Disability Research. 40:502–8, 1996.Google Scholar
Verhoeven, W. M., Veendrik-Meekes, M. J., Jacobs, G. A., Berg, Y. W. & Tuinier, S.Citalopram in mentally retarded patients with depression: a long-term clinical investigation. European Psychiatry: The Journal of the Association of European Psychiatrists. 16(2):104–8, 2001.Google Scholar
Welch, L. & Sovner, R.The treatment of a chronic organic mental disorder with dextromethorphan in a man with severe mental retardation. British Journal of Psychiatry. 161:118–20, 1992.Google Scholar
Zarcone, J. R., Hellings, J. A., Crandall, K.et al. Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal of Mental Retardation. 106(6):525–38, 2001.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Psychopharmacology in intellectual disabilities
    • By Bryan King, Professor and Vice Chair of Psychiatry and Behavioural Sciences, University of Washington
  • Edited by Nick Bouras, King's College London, Geraldine Holt, King's College London
  • Book: Psychiatric and Behavioural Disorders in Intellectual and Developmental Disabilities
  • Online publication: 15 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511543616.020
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Psychopharmacology in intellectual disabilities
    • By Bryan King, Professor and Vice Chair of Psychiatry and Behavioural Sciences, University of Washington
  • Edited by Nick Bouras, King's College London, Geraldine Holt, King's College London
  • Book: Psychiatric and Behavioural Disorders in Intellectual and Developmental Disabilities
  • Online publication: 15 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511543616.020
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Psychopharmacology in intellectual disabilities
    • By Bryan King, Professor and Vice Chair of Psychiatry and Behavioural Sciences, University of Washington
  • Edited by Nick Bouras, King's College London, Geraldine Holt, King's College London
  • Book: Psychiatric and Behavioural Disorders in Intellectual and Developmental Disabilities
  • Online publication: 15 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511543616.020
Available formats
×